Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MPLT | 8-K | neutral | 3/10 | MapLight Therapeutics CFO Vishwas Setia was separated effective immediately due to an HR violation, with no severance. T | Jun 18, 2026 |
| SNTI | S-3 | bearish | 7/10 | Senti Biosciences filed an S-3 shelf registration to register 15,971,890 shares of common stock for resale by its larges | Jun 18, 2026 |
| GRFS | 6-K | neutral | 3/10 | Grifols SA reported the results of its Ordinary General Shareholders' Meeting held on June 18, 2026. Shareholders approv | Jun 18, 2026 |
| LIXT | 8-K | bullish | 6/10 | LIXTE Biotechnology issued a $6.5 million secured promissory note to NOMAD Transportable Power Systems, the target of it | Jun 18, 2026 |
| MRNA | 144 | neutral | 2/10 | Former director Paul Sagan filed a Form 144 notice of intent to sell 25,770 shares of Moderna common stock, valued at ap | Jun 18, 2026 |
| BHST | 6-K | neutral | 3/10 | BioHarvest Sciences announced it will present at the 2026 BIO International Convention (June 22-25), showcasing its prop | Jun 18, 2026 |
| PVCT | 8-K | neutral | 2/10 | Provectus Biopharmaceuticals filed an 8-K furnishing its 2026 Annual Meeting of Stockholders presentation slides under R | Jun 18, 2026 |
| LNTH | COURT-RULING | bullish | 7/10 | The District Court of Delaware ruled that all asserted patents covering Lutathera (a cancer treatment) are invalid under | Jun 18, 2026 |
| TRIB | 6-K | mixed | 6/10 | Trinity Biotech reported Q1 2026 revenue of $10.8M (up 43% YoY from $7.6M), driven by rapid HIV and hemoglobin product s | Jun 18, 2026 |
| PFE | 8-K | neutral | 2/10 | Pfizer reaffirms full-year 2026 guidance following the CFO transition announcement on June 18, 2026. Revenue guidance re | Jun 18, 2026 |
| HCWB | S-1/A | neutral | 4/10 | HCW Biologics filed Amendment No. 1 to its S-1 as an exhibits-only filing to register the resale of shares and warrants | Jun 18, 2026 |
| CRVO | PRESS-RELEASE | bearish | 7/10 | CervoMed announced a registered direct offering of 2.5M shares at $4.00/share, raising $10M in gross proceeds. The dilut | Jun 18, 2026 |
| ALVO | 6-K | bearish | 6/10 | Alvotech closed its underwritten public offering and concurrent private placement, raising aggregate gross proceeds of a | Jun 18, 2026 |
| ADTX | CLUSTER | bearish | 7/10 | A mixed insider cluster at Aditxt shows HRT Financial LP buying ~$98K in shares, while DRW Securities sold a trivial amo | Jun 18, 2026 |
| PRTA | INSIDER-BUY | bullish | 5/10 | William P. Scully, a 10% owner of Prothena Corp, purchased $1.18M of PRTA shares in two open-market transactions at ~$8. | Jun 18, 2026 |
| CVKD | 8-K | neutral | 3/10 | Cadrenal Therapeutics announced plans to file a Rare Pediatric Disease Designation (RPDD) request with the FDA for tecar | Jun 18, 2026 |
| BIAF | 424B4 | bearish | 7/10 | bioAffinity Technologies priced a best-efforts public offering of 1,040,000 shares of common stock at $0.80 per share an | Jun 18, 2026 |
| PHGE | 8-K | neutral | 2/10 | BiomX filed an 8-K posting an updated investor presentation detailing its completed strategic transition from clinical-s | Jun 18, 2026 |
| DYAI | DEFA14A | bearish | 8/10 | Dyadic International filed a DEFA14A (definitive additional proxy soliciting material) disclosing receipt of a Nasdaq de | Jun 18, 2026 |
| CSCIF | 6-K | neutral | 2/10 | COSCIENS Biopharma Inc. reported results from its annual general and special meeting held June 17, 2026. All director no | Jun 18, 2026 |
| LGND | CLUSTER | neutral | 3/10 | Four LGND directors sold shares in a cluster totaling ~$2.5M in open-market sales following option exercises. The sales | Jun 18, 2026 |
| ETST | 8-K | neutral | 4/10 | Earth Science Tech reported fiscal 2026 revenue of $35.7M (+8% YoY), net income of $3.6M (+11% YoY), and EPS of $0.012 ( | Jun 18, 2026 |
| GRCE | 8-K | mixed | 5/10 | Grace Therapeutics filed an 8-K attaching its June 2026 corporate presentation, which provides an update on the FDA Comp | Jun 18, 2026 |
| CMND | 6-K | neutral | 4/10 | Clearmind Medicine announced it was granted a U.S. patent (No. 12,350,242) by the USPTO for its MEAI molecule covering c | Jun 18, 2026 |
| GRCE | 8-K | bearish | 6/10 | Grace Therapeutics reported FY2026 net loss of $7.8M ($0.47/share), improving from $9.6M ($0.79/share) in FY2025, driven | Jun 18, 2026 |
| RNAZ | 8-K | neutral | 4/10 | Transcode Therapeutics filed an 8-K furnishing an investor presentation that updates on its pipeline, including Phase 1a | Jun 18, 2026 |
| DNLI | 8-K | bullish | 6/10 | Denali Therapeutics (DNLI) announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 milli | Jun 18, 2026 |
| BCDA | PRESS-RELEASE, 8-K | neutral | 5/10 | BioCardia issued a shareholder letter following a recent capital raise, outlining key 2026 milestones: a planned Q4 2026 | Jun 18, 2026 |
| AIM | S-1 | bearish | 7/10 | AIM ImmunoTech filed a new S-1 registration statement to register 13,077,089 shares of common stock for resale by sellin | Jun 18, 2026 |
| DNLI | PRESS-RELEASE | bullish | 6/10 | Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in g | Jun 18, 2026 |